

Manuscript no. HAEMATOL/2011/044347 entitled “Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome. Final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group“

Authors: Baron Frédéric, Suciú Stefan, Amadori Sergio, Muus Petra, Zwierzina Heinz, Denzlinger Claudio, Michel Delforge, Thyss Antoine, Selleslag Dominik, Indrak Karel, Ossenkoppele Gert, and de Witte Theo

Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:

- Theo de Witte, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; T.deWitte@ncmls.ru.nl
- Stefan Suciú, EORTC Headquarters, Brussels, Belgium; stefan.suciú@eortc.be

According to the International Committee of Medical Journal Editors (ICMJE)

(http://www.icmje.org/ethical_1author.html): “Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the **conception of the study**: Stefan Suciú, Sergio Amadori, Heinz Zwierzina, Claudio Denzlinger, and Theo de Witte

3) **Design & Methods**. The following authors were responsible for specific investigations :

- Stefan Suciú, Sergio Amadori, Heinz Zwierzina, Claudio Denzlinger, and Theo de Witte participated to the design of the protocol.
- All authors but Frederic Baron and Stefan Suciú were co-investigators and contributed patients to the protocol.

4) **Results**. The following authors were responsible for specific portions of the results, including figures and tables :

- All figures: Suciú Stefan.
- All tables: Baron Frédéric & Suciú Stefan.
- Statistical analyses: Suciú Stefan.

5) **Writing the manuscript**. The following authors were responsible for writing the manuscript:

- Baron Frédéric (writing of the manuscript).
- Suciú Stefan (writing of the manuscript).
- de Witte Theo (editing of the manuscript).
- All other authors (minor editing of the manuscript and approval of the final version of the manuscript).

6) **Contributors Listed in Acknowledgments**: This publication was supported by grants number 5U10 CA11488-32 through 2U10 CA011488-41 from the National Cancer Institute (Bethesda, Maryland, USA) and by Fonds Cancer (FOCA) from Belgium. Its content is solely the responsibility of the authors and does not necessarily reflect the official views of the National

Cancer Institute. Centocor R&D, Inc., Great Valley Parkway, Malvern, PA, US, provided substantial financial support and *Remicade*® free of charge.

The following investigators/centers participated in this EORTC trial 06023.

Investigators	Center
Drs. Bron and Feremans	H. Univ. Bordet-Erasme, Brussels (B)
Dr. Selleslag	A.Z. St Jan, Brugge (BE)
Dr. Berneman	U.Z. Antwerpen (BE)
Dr. Vermeulen	C.H. La Tourelle, Verviers (B)
Drs. Verhoef and Delforge	U.Z. GASTHUISBERG, Leuven (B)
Drs. Thyss	Centre Lacassagne, Nice (F)
Drs. Marie and Vekhoff	Hotel-Dieu, Paris (F)
Drs. De Witte and Muus	Radboud UMC, Nijmegen (NL)
Dr. Ossenkoppele	Vrije Universiteit MC, Amsterdam (NL)
Dr. Willemze	Univ Med Ctr Leiden
Dr. Wijermans	Haga Zkh Leyenburg (NL)
Dr. Dengler	Univ.Klin.Heidelberg (DE)
Dr. Driessen	Eberhard Karls University, Tuebingen (DE)
Dr. Cermak	Institute Hematology, Prague (CZ)
Dr. Demuyneck	H. Hartziekenhuis, Roeselaere (BE)
Dr. Indrak	University Hospital, Olomouc (CZ)
Drs. Amadori and Buccisano	H. Tor Vergata, Roma (IT)

We thank the EORTC Headquarters members who took care of this study: Data Managers (Mr Filip Beeldens, Mrs Aurore Theys, Mrs Liv Meert), Clinical Research Physicians (Drs. Liliana Baila, Jocelyne Flament and Matthias Karrasch) and the Project Manager (Mrs Hilde Breysens).